Sandoz Group AG | Finanzwire

Basculer en Français

9979	Companies
202294	Keywords
132920	Articles
107424	Press releases

Home
Companies
Sandoz Group AG

BRIEF

published on 02/25/2026 at 07:05, 8 days 6 hours ago

Sandoz Reports Strong Financial Results and Forecasted Growth for 2026

Financial Results Operational Efficiencies 2026 Forecast Biosimilars Growth Generics Challenges
PRESS RELEASE

published on 02/25/2026 at 07:00, 8 days 6 hours ago

Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Sandoz reports strong full-year results for 2025 with net sales growth and core EBITDA margin expansion. The guidance for 2026 anticipates further growth in net sales and core EBITDA margin

Net Sales Growth Full-year Results Sandoz Financial Guidance 2026 Core EBITDA Margin Expansion
BRIEF

published on 02/23/2026 at 11:05, 10 days 2 hours ago

Sandoz Gains EU Approval for Ranluspec, Enhancing Biosimilars Position

European Commission Biosimilars Ophthalmology Sandoz Strategy Ranluspec Approval
PRESS RELEASE

published on 02/23/2026 at 11:00, 10 days 2 hours ago

Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Sandoz confirms European Commission approval for Ranluspec®, strengthening biosimilars leadership in ophthalmology. Launch planned for second half of 2026

Biosimilars Ophthalmology Sandoz European Commission Approval Ranluspec
BRIEF

published on 02/18/2026 at 07:05, 15 days 6 hours ago

Sandoz Expands Enzeevu® Label with FDA Approval for Retinal Indications

FDA Approval Biosimilars Sandoz Enzeevu Retinal Indications
PRESS RELEASE

published on 02/18/2026 at 07:00, 15 days 6 hours ago

Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label to include multiple retinal indications, offering new treatment options for retinal diseases

FDA Approval Vision Care Sandoz Enzeevu Retinal Indications
BRIEF

published on 01/14/2026 at 12:05, 1 month 22 days ago

Sandoz Secures EU Approval for Ondibta® in Diabetes Treatment

European Commission Biosimilars Diabetes Treatment Ondibta® Approval Sandoz Strategy
PRESS RELEASE

published on 01/14/2026 at 12:00, 1 month 22 days ago

Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes. Expected launch by early 2027

Diabetes European Commission Biosimilars Sandoz Ondibta
BRIEF

published on 01/12/2026 at 15:05, 1 month 23 days ago

Sandoz Unveils Strategy for 'Golden Decade' of Affordable Medicines

Market Strategy Biosimilars Sandoz Group AG Golden Decade Affordable Medicines
PRESS RELEASE

published on 01/12/2026 at 15:00, 1 month 23 days ago

Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented ’golden decade’ of affordable medicines opportunity
Sandoz CEO to outline plans for capturing the unprecedented 'golden decade' of affordable medicines opportunity at the 44th Annual J.P. Morgan Healthcare Conference

CEO Sandoz J.P. Morgan Healthcare Conference Golden Decade Affordable Medicines

Accesswire

Published on 03/05/2026 at 13:40, 16 minutes ago

Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences
Published on 03/05/2026 at 13:30, 26 minutes ago

Vox Royalty Provides 2026 Guidance and Increases Quarterly Dividend
Published on 03/05/2026 at 13:30, 26 minutes ago

Nextech3D.ai Expands AI Event Technology Into New Markets and Implements 20%-30% Enterprise Price Increase
Published on 03/05/2026 at 13:00, 56 minutes ago

Revolve Signs Definitive Agreements for Portfolio of 16 Distributed Generation Solar Projects in Mexico
Published on 03/05/2026 at 13:00, 56 minutes ago

Field Work Identifies New Mineralized Trend and Additional Gold Targets at Golden Rose

View all ACCESSWIRE

EQS Group

Published on 03/05/2026 at 13:43, 13 minutes ago

Healthcare specialist SHS Capital exits AMW, a leading specialty pharma company, and continues partnership by reinvesting with its current fund as part of a syndicate of investors
Published on 03/05/2026 at 13:25, 31 minutes ago

Huawei and SOLUM Unveil Shop-in-Shop Smart Converged Network Solution to Accelerate Retail Intelligence
Published on 03/05/2026 at 13:06, 49 minutes ago

HENSOLDT acquires Nedinsco and expands its European presence
Published on 03/05/2026 at 13:05, 51 minutes ago

Norgine announces £23 million new investment as part of more than £50 million committed to expanding medicines manufacturing in Wales
Published on 03/05/2026 at 13:00, 56 minutes ago

Huawei Launches AI Data Platform to Bridge Models and Business Value

Les Echos

Published on 03/05/2026 at 13:20, 35 minutes ago

Voting rights
Published on 03/05/2026 at 07:30, 6 hours 26 minutes ago

Share buyback finalized
Published on 03/04/2026 at 23:50, 14 hours 6 minutes ago

Total number of voting rights and shares making up the share capital at February 28, 2026
Published on 03/04/2026 at 18:00, 19 hours 56 minutes ago

Disclosure of Share Capital and Voting Rights as of February 28, 2026
Published on 03/04/2026 at 17:45, 20 hours 11 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE